There was no observable difference in therapeutic effect between the patients receiving the omega-3 and the placebo group.

However, when the researchers took into account which of the patients carried the susceptibility gene APOE4 and which did not, an appreciable difference appeared.

Carriers of the gene who had received active treatment responded positively to the omega-3 as regards agitation symptoms, while non-bearers of the gene showed an improvement in depressive symptoms.

However, no therapeutic recommendations can be made out of these results yet, not until larger studies on individuals with more pronounced neuropsychiatric symptoms are conducted.

Findings have been reported in an article recently published in the International Journal of Geriatric Psychiatry.

Read the full report.

Post from: Blisstree

Omega-3 Supplements Against Alzheimer’s Symptoms